Mutations in the insulin promoter factor-1 gene in late-onset type 2 diabetes mellitus

A F Reis, W-Z Ye, D Dubois-Laforgue, C Bellanné-Chantelot, J Timsit and G Velho

INSERM Unité 342, Institut Cochin de Génétique Moléculaire, Paris, France, 1Service d’Immunologie Clinique, Hôpital Necker-Enfants Malades, Paris, France and 2Fondation Jean Dausset Centre d’Étude du Polymorphisme Humain, Paris, France

(Correspondence should be addressed to G Velho, INSERM U-342, Hôpital Saint Vincent-de-Paul, 82 Avenue Denfert Rochereau, 75014 Paris, France; Email: gvelho@infobiogen.fr)

Abstract

Objective: Insulin promoter factor-1 (IPF-1) is a transcription factor expressed in pancreatic beta cells. Following the identification of missense variants in the coding regions of the IPF-1 gene, in subjects selected for a strong family history of type 2 diabetes, the aim of our study was to evaluate the prevalence of these variants in the common form of type 2 diabetes.

Methods: Three variants (C18R, Q59L and D76N) were screened by PCR-RFLP in a group of 296 unrelated French late-onset type 2 diabetic subjects consecutively recruited in a diabetes department of a university hospital, regardless of family history of diabetes.

Results: The C18R and Q59L variants were each found in 0.37% of the diabetic patients, and in none of 147 controls. We did not detect the D76N variant, which was the most frequent variant in subjects with a strong family history of diabetes, in patients or controls.

Conclusions: We have observed a combined prevalence of missense variants in the coding region of the IPF-1 gene of around 1%, in unselected patients with the common form of late-onset type 2 diabetes. The prevalence of these variants in subjects with a strong family history of type 2 diabetes had been found to be as high as ~6%. These differences in prevalence might be related to differences in the clinical profile of patients, such as age of onset of diabetes and associated obesity, as well as a family history of diabetes.

European Journal of Endocrinology 143 511–513
A F Reis and others

Table 1 Demographic and clinical profile of patients and controls.
Data are expressed as means ± S.D.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (n)</td>
<td>296</td>
<td>143</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>59%/41%</td>
<td>50%/50%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 12</td>
<td>61 ± 16</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29.3 ± 5.9</td>
<td>30.3 ± 6.1</td>
</tr>
<tr>
<td>Age of diagnosis of diabetes (years)</td>
<td>50 ± 11</td>
<td>53 ± 9</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>13 ± 9</td>
<td>12 ± 9</td>
</tr>
<tr>
<td>Treatment (OHA/insulin)</td>
<td>59%/41%</td>
<td>56%/44%</td>
</tr>
<tr>
<td>Prevalence of obesity</td>
<td>38%</td>
<td>35%</td>
</tr>
<tr>
<td>Prevalence of hypertension</td>
<td>67%</td>
<td>62%</td>
</tr>
<tr>
<td>Total cholesterol &gt; 6 mmol/l (%)</td>
<td>34%</td>
<td>37%</td>
</tr>
<tr>
<td>Triglycerides &gt; 2 mmol/l (%)</td>
<td>51%</td>
<td>54%</td>
</tr>
</tbody>
</table>

OHA, oral hypoglycaemic agents.
Obesity was defined as BMI ≥ 30 kg/m².
Hypertension was defined as: 1) systolic blood pressure (SBP) greater than 140 mmHg and/or a diastolic blood pressure (DBP) greater than 85 mmHg, 2) SBP and/or DBP below these values in the presence of antihypertensive medication and history of hypertension.

with late-onset diabetes or with MODY in the probands’ families, where both unaffected carriers and affected non-carriers (phenocopies) were observed. Nevertheless, it was suggested that these variants predispose to type 2 diabetes, as they are associated with decreased transcriptional activation of the insulin gene promoter in vitro, and with decreased insulin secretion in non-diabetic carriers in vivo (12, 13).

The aim of our study was to assess the prevalence of these variants in the common form of late-onset type 2 diabetes. We screened a group of unrelated French type 2 diabetic subjects, consecutively recruited from the diabetes department outpatient clinics of a university hospital, regardless of familial history of diabetes.

Materials and methods

Subjects
We studied a group of 296 unrelated Caucasian subjects presenting with overt late-onset type 2 diabetes mellitus according to the revised criteria (14), and consecutively recruited at the diabetes department and outpatient clinics of Hôpital Necker, Paris, France. All subjects were tested for islet cell autoantibodies (ICA) and none had positive results. The control group consisted of 147 unrelated Caucasians subjects without known history of diabetes, recruited among members of CEPH family reference panel (one per family) and among spouses of subjects with type 2 diabetes. Demographic and clinical characteristics of patients and controls are shown in Table 1. The study was approved by the ethical committee of Hôpital Necker (CCPPRB Paris Necker).

DNA analysis
DNA was extracted from peripheral blood leukocytes by standard procedures, and genotypes were determined by Polymerase chain reaction/Restriction fragment-length polymorphism analyses (PCR-RFLP). The T→C transition in codon 18 resulting in the substitution of cysteine by arginine (C18R) was screened with the primers and conditions described by Hani and co-workers (13). The G→A transition at codon 59 resulting in the substitution of a glutamine by leucine (Q59L), and the G→A transition at codon 76 resulting in the substitution of an aspartic acid by asparagine (D76N) were screened as described by Hani and co-workers (12). All experiments included a positive sample for the variant being tested.

Results
The C18R variant was seen only in one diabetic subject out of the 272 tested (0.37%) and in none of 147 controls. The carrier is a 62-year-old woman, diagnosed at the age of 51 years and treated since then by oral hypoglycaemic agents, and without any known family history of diabetes. She is obese (body mass index (BMI) 34.8 kg/m²), hypertensive and presented high triglycerides levels. The Q59L variant was also observed in only one diabetic subject out of 272 (0.37%) and in none of the controls. The carrier is a 71-year-old woman, diagnosed at the age of 67 years and treated since then by oral hypoglycaemic agents. She reports a family history of diabetes (mother and paternal grandmother). The patient is obese (BMI 34.8 kg/m²), hypertensive and has documented coronary heart disease. The D76N mutation was not found in any of the 296 diabetic subjects nor in the controls.

Discussion
The prevalences of the C18R and Q59L variants in our cohort are similar to those reported in the studies of diabetic patients with a strong family history of diabetes, confirming that they are very rare. The C18R variant was observed in 0.51% of the probands and in none of the controls in the British study (13), and the Q59L variant was observed in 0.52% of the probands and in none of the controls in the French study (12). We have not tested the R197H variant, seen only in one British patient. As for the D76N variant, which was not found in patients or controls from our cohort, it was observed in 2.06% of the probands and 1.04% of the controls in the British study (13) and in 4.68% of the probands and in 0.43% of the controls in the French study (12). Incidentally, we have observed this variant in the proband from a Brazilian MODY family, who was subsequently found to carry also an HNF-1α/MODY3 mutation (data not shown). However, the HNF-1α mutation but not the IPF-1 D76N variant co-segregated with diabetes in that family.

These differences in prevalence of the D76N variant might be related to the different clinical profiles of diabetes in the three studies. Unlike our patients,
subjects in the French and British studies were selected for a strong family history of diabetes, and all had at least one first-degree relative with type 2 diabetes. Forty-three percent of our patients reported a history of diabetes in a first-degree relative. However, we have not tested these family members, and thus this information is less reliable than that obtained in the other studies. Moreover, the average age of diagnosis of diabetes and the BMI were both higher in our patients (50 ± 11 years and 29.3 ± 5.9 kg/m² respectively; means ± s.d.) and they were less often treated by insulin (41%) than the French subjects with familial type 2 diabetes studied by Hani and co-workers (42% and 25.3 ± 3.8 kg/m² and 49%) (12). These observations suggest that they may represent different sub-sets of type 2 diabetes patients, despite the common geographical origin of both samples. In the British study, the age of diagnosis of diabetes was higher (56 ± 9 years), the BMI intermediate (28.1 ± 4.9 kg/m²) and the frequency of treatment by insulin lower (36%) than in our study and in the French study of familial type 2 diabetes. It is noteworthy that the prevalence of the insulin gene promoter in vitro not associated with decreased transcriptional activation of the insulin gene in late-onset type 2 diabetes. Moreover, the two variants were found in only one out of 200 (0.5%) Danish subjects with late-onset type 2 diabetes, of whom at least 33% had a strong family history of diabetes (10). No other missense mutation was found in that study, except for an A140T variant showing no co-segregation with diabetes in a Danish MODY family. Moreover, the two variants were not associated with decreased transcriptional activation of the insulin gene promoter in vitro (10).

In conclusion, variants in the IPF-1 gene may predispose to type 2 diabetes, probably in a polygenic and multifactorial context. Although their combined prevalence was found to be as high as ~6% in subjects selected for a strong familial history of type 2 diabetes (12), our data suggest a much lower prevalence, around 1%, in unselected patients with the common form of late-onset type 2 diabetes.

Acknowledgements

This work was supported by grants from INSERM/Merck, Sharp Dhome and Chibret for research in Clinical Investigation Centres (INSERM CIC 9303 NEM), the 'Fondation pour la Recherche Médicale', and Lilly, France. AF Reis is supported by a doctoral grant from CAPES, Brasilia, Brazil, and WZ Ye by a grant from AJD, France.

References

1 Froguel P & Velho G. Molecular genetics of maturity onset diabetes of the young. Trends in Endocrinology and Metabolism 1999 10 142–146.

Received 4 April 2000
Accepted 29 June 2000